What Is CJC-1295?

CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) that was engineered to extend the half-life and biological activity of the endogenous hormone. Researchers investigating what is CJC-1295 often focus on its ability to stimulate the pulsatile release of growth hormone without the rapid degradation seen in its precursors. By utilizing Drug Affinity Complex (DAC) technology, the peptide remains active in vivo for significantly longer durations than earlier iterations.

Mechanism of Action: The GHRH Analogue At the molecular level, CJC-1295 functions as a secretagogue. It binds to the GHRH receptor in the anterior pituitary gland, mimicking the action of naturally occurring growth hormone-releasing hormone. Unlike native GHRH, which has a half-life of less than ten minutes, CJC-1295 is designed to resist enzymatic cleavage by dipeptidyl peptidase-4 (DPP-IV).

The modification involves the addition of a lysine residue bound to a reactive group called the Drug Affinity Complex (DAC). This allows the peptide to bond covalently to circulating albumin after administration. Because albumin is a stable, long-lived protein in the bloodstream, the peptide remains active and avoids rapid renal clearance. This prolonged action allows for a steady increase in plasma levels of growth hormone and, subsequently, Insulin-like Growth Factor 1 (IGF-1), which mediates many of the system-wide effects of GH.

Pharmacokinetics and the DAC Distinction When exploring what is CJC-1295, it is critical to distinguish between the two primary forms studied in laboratory settings: CJC-1295 with DAC and CJC-1295 without DAC (frequently referred to as Mod GRF 1-29).

1. CJC-1295 with DAC: This version exhibits a half-life of approximately 6 to 8 days. In clinical trials involving healthy adults, a single dose was shown to increase mean plasma growth hormone concentrations by 2-fold to 10-fold for a period of up to six days.
2. CJC-1295 without DAC (Mod GRF 1-29): This is a tetrasubstituted version of the original GRF 1-29. Its half-life is measured in minutes (roughly 30 minutes), requiring more frequent administration to maintain elevated GH levels.

Research indicates that the DAC version provides a baseline "bleed" or elevation of GH, while the non-DAC version is often utilized in studies looking to mimic the natural pulsatile rhythm of the endocrine system.

Research Findings on Systemic Impact Peer-reviewed data on CJC-1295 suggests several primary areas of physiological impact. Because growth hormone is a master regulator of metabolism and tissue repair, the downstream effects of CJC-1295 are diverse:

Protein Synthesis and Muscle Tissue Hypertrophy and tissue repair are central themes in GH research. By elevating GH and IGF-1, CJC-1295 promotes nitrogen retention and protein synthesis. Laboratory observations in animal models suggest enhanced recovery of myofibrils following exertion or injury. This has led to comparative studies involving other regenerative peptides like BPC-157.

Adipose Tissue Metabolism GH is known to exert lipolytic effects. Research has demonstrated that sustained elevations in GH can lead to a reduction in visceral adipose tissue. This occurs through the activation of hormone-sensitive lipase and the inhibition of lipoprotein lipase, effectively shifting the metabolic focus toward the oxidation of fatty acids.

Pituitary Feedback Loops One of the notable findings in CJC-1295 research is that it preserves the negative feedback loop of the pituitary-hypothalamic axis. Unlike exogenous GH administration, which can suppress natural production, CJC-1295 works by stimulating the gland's own capacity, though chronic long-acting stimulation (with DAC) continues to be studied for its long-term effects on receptor sensitivity.

Synergistic Potential in Laboratory Models In many research protocols, CJC-1295 is paired with Growth Hormone Releasing Peptides (GHRPs) such as Ipamorelin. This synergy is of particular interest to endocrinology researchers. While GHRH analogs like CJC-1295 ensure the "amplitude" of the GH pulse, GHRPs act as ghrelin mimetics that trigger the "timing" or onset of a pulse while inhibiting somatostatin (the hormone that shuts down GH release).

Combining these two classes of secretagogues has been shown to produce a significantly more robust GH discharge than using either compound in isolation. This "dual action" approach allows researchers to observe maximal pituitary output while using lower concentrations of each individual peptide.

Handling, Reconstitution, and Storage CJC-1295 is typically synthesized as a lyophilized (freeze-dried) powder to ensure molecular stability during transit and storage. For laboratory use, proper reconstitution is vital to prevent degradation.

* Solvent: Bacteriostatic water (0.9% benzyl alcohol) is the standard diluent for multidose research vials to prevent bacterial growth. * Technique: The solvent should be introduced slowly down the side of the glass wall to avoid vigorous foaming, which can denature the delicate peptide bonds. * Temperature: Once reconstituted, the peptide is highly sensitive to thermal fluctuations. It should be stored at 2°C to 8°C (36°F to 46°F). In its lyophilized state, it is stable at room temperature for short periods but should be kept in a freezer for long-term preservation.

Limitations and Future Outlook Despite the robust data regarding the efficacy of CJC-1295 in elevating GH levels, research is ongoing regarding the physiological implications of "GH bleed." Constant stimulation of the pituitary gland via the long-acting DAC version may lead to different metabolic outcomes than the pulsatile stimulation provided by shorter-acting analogs.

Additionally, researchers must account for individual variability in pituitary sensitivity. Factors such as age, baseline GH levels, and the presence of somatostatin inhibitors can all influence the quantitative results of a study. Future research aims to refine the understanding of how long-term GH secretagogue exposure affects glucose metabolism and insulin sensitivity, as GH is known to have slightly diabetogenic properties at high concentrations.

Frequently Asked Questions

Q: What is the primary difference between CJC-1295 and Mod GRF 1-29? The primary difference lies in the half-life. CJC-1295 usually refers to the "DAC" version, which has an extended half-life of 6–8 days due to its ability to bind to albumin. Mod GRF 1-29 is the same basic peptide sequence but lacks the DAC component, resulting in a half-life of approximately 30 minutes, necessitating more frequent application in research settings.

Q: Does CJC-1295 affect natural growth hormone production? CJC-1295 is an analog of GHRH, meaning it stimulates the pituitary gland to release its own stored growth hormone. While it increases the output, it does not typically "shut down" the pituitary in the way that direct exogenous growth hormone can, though researchers continue to study the effects of chronic stimulation on receptor desensitization.

Q: Why is CJC-1295 often studied alongside [Ipamorelin](/research/hubs/ipamorelin)? They are studied together because they target different receptors to achieve a similar goal. CJC-1295 mimics GHRH, while Ipamorelin mimics ghrelin. When used together, they create a synergistic effect that results in a significantly higher release of growth hormone than if either peptide were used alone, by simultaneously stimulating the pituitary and inhibiting somatostatin.

Q: What are the storage requirements for CJC-1295? In its lyophilized (powder) form, CJC-1295 is stable at room temperature for several weeks but should be stored in a freezer for long-term stability. Once reconstituted with a bacteriostatic agent, it must be refrigerated at all times and used within a specific window (usually 21-28 days) to ensure maximum potency and prevent degradation.

Research Use Only. This content is intended for laboratory and research purposes only. Not for human consumption, diagnosis, or treatment.